THP-1 CDX Model
The THP-1 cell line is derived from human acute monocytic leukemia, a subtype of acute myeloid leukemia (AML). AML is a heterogeneous hematological malignancy characterized by the rapid proliferation of immature myeloid cells, leading to impaired hematopoiesis and bone marrow failure. THP-1 serves as an indispensable tool for understanding the complex biology, progression, and therapeutic challenges associated with AML, particularly the monocytic subtype. Reflecting key molecular features and genetic mutations often seen in AML patients, THP-1 plays a vital role in preclinical research. Its in vitro and in vivo behavior provides deep insights into leukemic cell growth dynamics, interaction with the bone marrow microenvironment, and sensitivity to therapeutic agents. Researchers widely utilize the THP-1 model to study the molecular drivers of AML, assess the efficacy of potential therapeutic agents, and investigate resistance mechanisms to current treatments.
Cancer Location: Intravenous
Cancer Type: Acute Myeloid Leukemia
Model Name: THP-1
Mouse Strain: NOG, NSG
THP-1 Growth Curves
Growth of subcutaneous THP-1 in mice (n=5 mice)